bims-livmat Biomed News
on Living materials
Issue of 2026–11–01
six papers selected by
Sara Trujillo Muñoz, Leibniz-Institut für Neue Materialien



  1. Front Syst Biol. 2026 ;6 1905585
      Engineered Living Materials (ELMs) combine living cells with matrices, interfaces, environmental fields, and sometimes electronic or computational controllers. Their multicomponent architecture creates an attribution problem: the same observed output may reflect passive material physics, active cellular regulation, interface or morphological change, environmental gradients, controller adaptation, or coupled-system dynamics. This article proposes ELM-CLAIM (Engineered Living Materials-Controls for Learning, Adaptation, Intelligence, and Memory), an author-proposed claim-calibration and reporting framework for matching adaptive vocabulary to measurable state variables, temporal criteria, attribution targets, and evidence classes. The framework classifies specific behaviors from passive responsiveness (L0) through active responsiveness (L1), adaptation (L2), memory-like behavior (L3), learning-like behavior (L4), and autonomous goal-directedness (L5). It also provides an evidence-tiered claim-to-control matrix, proportional substitution rules for experimentally intractable controls, component- and controller-level attribution logic, model-transparency requirements, and a reviewer-oriented reporting checklist. Essential entries denote evidential functions rather than a single mandatory assay, allowing justified orthogonal controls while requiring claims to be lowered when major alternatives remain unresolved. Published cases are used illustratively to stress-test interpretability rather than to validate the framework statistically. ELM-CLAIM calibrates language; it does not by itself validate an experiment, define cognition, or constitute a community standard. Community testing, inter-reviewer reliability assessment, and prospective experimental use remain necessary next steps.
    Keywords:  adaptive materials; attribution; biohybrid systems; claim calibration; engineered living materials; experimental controls; learning-like behavior; memory-like behavior
    DOI:  https://doi.org/10.3389/fsysb.2026.1905585
  2. Int J Pharm. 2026 Oct 29. pii: S0378-5173(26)01058-6. [Epub ahead of print] 127609
      The minimally invasive delivery of therapeutics across biological barriers is a major challenge in modern medicine. Microneedles (MNs) are novel platforms to address this challenge effectively. Simultaneously, the therapeutic potential of live microorganisms has been harnessed for various biomedical applications. The integration of living microorganisms with MNs has recently emerged as a promising strategy that combines minimally invasive delivery with dynamic biological functions. This review explores the integration of different microorganisms (probiotics, commensal bacteria, pathogenic and engineered bacteria, and microalgae) into MNs for various biomedical applications such as chronic skin conditions, wound dressing, cancer therapy, and intradermal vaccination. In preclinical studies, these platforms generally showed improved outcomes compared with free microorganisms, microorganism-free MNs, or conventional treatments used as controls. Furthermore, combining microorganisms with photothermal agents, sonosensitizers, antibiotics, and nanozymes can further enhance therapeutic performance. Synergistic mechanisms in these platforms - such as targeted pathogen killing, microenvironment remodeling (hypoxia alleviation and glucose consumption), and in situ generation of gases and metabolites - highlight their potential as a new class of localized therapies. Finally, the current challenges along with the future potential applications of these emerging platforms are discussed in detail.
    Keywords:  Bacteria; Microalgae; Microneedles; Microorganisms; Probiotics
    DOI:  https://doi.org/10.1016/j.ijpharm.2026.127609
  3. Adv Mater. 2026 Oct 26. pii: e75118. [Epub ahead of print]
      Conventional static biomaterials and synthetic nanomedicines struggle to penetrate recalcitrant biofilms and orchestrate tissue regeneration in deep-seated infections due to limited autonomous navigation and a lack of spatiotemporal responsiveness. Here, we conceptualize and develop a programmable engineered living vehicle (ELV) that functions as an autonomous biofactory for the synergistic management of drug-resistant osteomyelitis. Built upon a self-propelled Escherichia coli Nissle 1917 chassis with innate ecological dominance, these living biofactories are hierarchically equipped with environmental biosensors and logic-gated computing modules. Crucially, leveraging AlphaFold 3-guided molecular docking, we engineered multiscale thermo-responsive genetic logic circuits that enable precise, temperature-dependent biomanufacturing of bacteriolytic lysostaphin (LYS) and vasoactive intestinal peptide (VIP) (≥37°C), coupled with a fail-safe thermal self-destruct mechanism (≥42°C). Furthermore, surface-engineered (DSS)6 peptides confer robust hydroxyapatite affinity, acting as a bone-homing navigation module. In a rat osteomyelitis model induced by methicillin-resistant Staphylococcus aureus (MRSA), intravenously deployed ELV biofactories autonomously navigate to the infected niche, actively penetrate biofilms, and outperform vancomycin in pathogen clearance. Concurrently, localized payload secretion reprograms the osteo-immune microenvironment, significantly accelerating bone repair. This work establishes a versatile paradigm for next-generation smart living therapeutics, bridging synthetic biology with micro-engineering to address complex clinical challenges.
    Keywords:  bone regeneration; engineered living vehicles; osteo‐immunomodulation; synthetic biology
    DOI:  https://doi.org/10.1002/adma.75118
  4. Front Bioeng Biotechnol. 2026 ;14 1864003
      Anxiety disorders are highly prevalent worldwide, yet effective treatment strategies remain limited. Overactive gut-brain communication has been linked to anxiety-like behaviors, and modulation of this signaling offers a promising approach for anxiety reduction. Leveraging the controllable release and biocompatibility of engineered bacteria, we developed a near-infrared (NIR)-responsive probiotic system that releases gamma-aminobutyric acid (GABA) to directly modulate gut vagal sensory input, thereby alleviating anxiety-like behavior. The system was constructed using Escherichia coli Nissle 1917 (EcN) carrying a thermosensitive GABA synthesis plasmid (EcN-Gadabc), coated with polydopamine (pDA), and further conjugated with a pepT1 targeting peptide for small-intestinal targeting. This design enabled precise NIR-triggered GABA release in the gut, improved bacterial survival under simulated gastrointestinal conditions, and enhanced intestinal retention following oral administration. In mice subjected to repeated restraint stress, treatment with the engineered bacteria under NIR irradiation alleviated anxiety-like behaviors, remodeled the gut microbiota, reduced the relative abundance of Clostridium, decreased serum IL-1β, IL-6 and TNF-α, increased IL-10, and reduced c-fos-positive neurons in the amygdala, nucleus tractus solitarius, and locus coeruleus. Transcriptomic analysis further indicated alterations in pathways associated with neuronal excitability, ion channel activity and calcium signaling. These findings support a non-invasive and remotely controllable strategy for gut-brain axis modulation using engineered probiotics and highlight its potential for precision bacteriotherapy in anxiety-related disorders.
    Keywords:  anxiety disorder; engineered probiotic; gamma-aminobutyric acid; gut-brain axis; optogenetics
    DOI:  https://doi.org/10.3389/fbioe.2026.1864003
  5. FEMS Yeast Res. 2026 Oct 30. pii: foag058. [Epub ahead of print]
      Yeast platforms are rapidly transitioning from traditional eukaryotic model organisms to versatile, programmable chassis for next-generation human health applications. This review systematically examines the translational evolution of conventional and non-conventional yeasts including Saccharomyces cerevisiae, Komagataella phaffii, Saccharomyces boulardii, and Yarrowia lipolytica and redefines them as scalable biomanufacturing factories and advanced living therapeutics. We highlight milestone advancements in synthetic biology toolkits that lower technical barriers, such as CRISPR-mediated multiplex editing, modular cloning frameworks, and high-throughput secretion screening. We focus on sophisticated glycoengineering strategies for humanized N-glycosylation, alongside data-driven paradigms that leverage artificial intelligence to predict gene expression and streamline strain design. In clinical domains, we detail the established success of yeast in producing subunit or virus-like particle vaccines (e.g. HBV and HPV) and therapeutic enzymes (e.g. ecallantide), alongside its emerging role as gut-adapted live biotherapeutic products (LBPs) engineered for in situ delivery and biosensing. Finally, we explore specialized non-conventional platforms, focusing on lipid- and acetyl-CoA-rich hosts for lipophilic drug discovery, and stress-tolerant systems optimized for economical, feedstock-flexible bioprocesses. In summary, this review underscores the integrated value of yeast systems across disease modeling, industrial manufacturing, and clinical intervention, charting future directions to address global health challenges.
    Keywords:  Live biotherapeutic products (LBPs); Non-conventional yeasts; Therapeutic proteins and antibodies; Yeast cell factories
    DOI:  https://doi.org/10.1093/femsyr/foag058
  6. Adv Healthc Mater. 2026 Oct 28. pii: e71906. [Epub ahead of print]
      The convergence of synthetic biology, materials science, and artificial intelligence drives a transformative shift in biopharmaceutical research, advancing from passive drug carriers to intelligent, programmable therapeutics. This review evaluates artificial and biomimetic cells as a framework that connects fundamental biological discovery with clinical translation. It examines five key technological pathways: membrane-engineered artificial cells, membraneless organelle (MLO) systems, multicompartmental artificial cells, protocell communication networks, and virtual cells. These platforms enable precise regulation of drug stability, targeting, biosynthesis, and adaptive responsiveness. Recent progress includes microenvironment-triggered release, logic-gated intercellular communication, and virtual cell-assisted high-throughput screening and toxicity prediction. Despite these advances, challenges remain in scalable manufacturing, long-term stability, and regulatory adaptation. The integration of closed-loop learning, interpretable models, and advanced biomanufacturing will be essential to position artificial and biomimetic cell systems at the forefront of next-generation precision medicine.
    Keywords:  artificial cells; biomanufacturing; biomimetic cells; drug delivery; protocell networks; synthetic biology; virtual cells
    DOI:  https://doi.org/10.1002/adhm.71906